ReviewTouchREVIEWS in endocrinology2023
Thyrotoxic Cardiomyopathy: State of the Art.
Review in TouchREVIEWS in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence and Risk Factors of Heart Failure in Patients Diagnosed with Hyperthyroidism: A Systematic Review and Meta-analysis.TouchREVIEWS in endocrinology · 2024Pooled it
- Mechanical circulatory support for haemodynamic protection in patients with heart failure during non-cardiac surgery.American heart journal plus : cardiology research and practice · 2026Article
- Thyrotoxicosis in MCT8 deficiency.The Journal of clinical endocrinology and metabolism · 2026Review
- Hypertrophic cardiomyopathy is not the sole echocardiographic phenotype associated with hyperthyroidism in cats: a retrospective study in 147 cats (2005-2025).Journal of veterinary internal medicine · 2026Article
- Postpartum Thyroiditis Complicated by Peripartum Cardiomyopathy and Right Ventricular Thrombi: A Case Report from Rural Uganda.International medical case reports journal · 2026Article
- Thyroid storm-induced cardiovascular complications and modalities of therapy: Up-to-date review.World journal of critical care medicine · 2025Review
- Severely Dilated Cardiomyopathy and Cardiogenic Shock in a Patient With Thyroid Storm.JCEM case reports · 2025Article
- Cardiomyopathies of endocrine origin: A state-of-the-art review.World journal of cardiology · 2025Review
- The impact of thyroid disorder on cardiovascular disease: Unraveling the connection and implications for patient care.International journal of cardiology. Heart & vasculature · 2024Review
- Article
- A Rare Encounter: Unstable Vasospastic Angina Induced by Thyrotoxicosis.Journal of clinical medicine · 2024Article
- Cardiac evaluation in amiodarone-induced thyroid dysfunction with suspected cardiac ischemia?: a case report and review of the literature.Journal of medical case reports · 2024Review
- Thyrotoxic Cardiomyopathy: A Rare Case of Thyroid Storm Presenting as De Novo Heart Failure.Cureus · 2024Article
- Thyroid and cardiovascular diseases.Turkish journal of medical sciences · 2024Review
- Unusual Presentations of Thyrotoxic Tricuspid and Mitral Regurgitations in 62 Adults: A Systematic Review of Case Reports with In-depth Pathophysiological Review.European cardiology · 2024Review
- Article
- Echocardiographic diagnosis of hypertrophic cardiomyopathy confined to the left ventricular apex in a cat.JFMS open reportsArticle
- Coincident Thyrotoxic Hypokalemic Periodic Paralysis and Cardiomyopathy.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid hormones, mainly triiodothyronine, have genomic and non-genomic effects on cardiomyocytes related to the contractile function of the heart. Thyrotoxicosis, which is the set of signs and symptoms derived from the excess of circulating thyroid hormones, leads to increased cardiac output and decreased systemic vascular resistance, increasing the volume of circulating blood and causing systolic hypertension. In addition, the shortening of the refractory period of cardiomyocytes produces sinus tachycardia and atrial fibrillation. This leads to heart failure. Approximately 1% of patients with thyrotoxicosis develop thyrotoxic cardiomyopathy, a rare but potentially fatal form of dilated cardiomyopathy. Thyrotoxic cardiomyopathy represents a diagnosis of exclusion, and prompt identification is crucial as it is a reversible cause of heart failure, and heart function can be recovered after achieving a euthyroid state using antithyroid drugs. Radioactive iodine therapy and surgery are not the best initial therapeutic approach. Moreover, it is important to manage cardiovascular symptoms, for which beta blockers are the first-line therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.